Introduction
============

*Streptococcus pneumoniae*, the pneumococcus, is an obligate commensal of the human nasopharynx and a worldwide opportunistic pathogen. *S. pneumoniae* causes non-invasive diseases such as acute otitis media, sinusitis, and pneumonia, as well as invasive diseases such as sepsis and meningitis ([@B36]). Antibiotic therapy for community-associated upper respiratory tract bacterial infections where *S. pneumoniae* is suspected often includes a macrolide ([@B46]; [@B22]). In the United States, macrolides are one of the most prescribed antibiotics with 190 prescriptions per 1000 people in 2011 ([@B22]). However, macrolide effectiveness has been compromised by the emergence of macrolide resistance in *S. pneumoniae* in the early to mid-1990s ([@B17]; [@B23]). The continuing widespread use of macrolides has resulted in a strong selective pressure contributing to the expansion of macrolide-resistant *S. pneumoniae* ([@B3]). While the pneumococcal conjugate vaccines (PCV7, PCV13), introduced in the US in 2000 and 2010, respectively, have significantly reduced the burden of pneumococcal disease as well as the overall incidence of antibiotic resistance in pneumococci, the strong selection pressure for resistance continues in the population.

Macrolide resistance in *S. pneumoniae* is predominantly due to ribosomal modification or macrolide efflux/ribosomal protection ([@B37]; [@B42]; [@B34]; [@B45]). Macrolides bind to the 23S rRNA (predominantly at residue A2058 for *Escherichia coli*) of the 50S ribosome to inhibit protein synthesis ([@B50]). A ribosomal methyltransferase, encoded by *erm*(B), prevents binding of macrolides by dimethylating the target site on the ribosome ([@B49]). Ribosomal methylation results in high-level macrolide resistance (erythromycin MIC \> 256 μg/ml) as well as resistance to lincosamides and streptogramin B (the MLS~B~ phenotype). *erm*(B) is carried on a group of mobile genetic elements including the *erm*(B) element and complex elements including the *erm*(B) element inserted into Tn*916* (Tn*6002);* or *erm*(B) is carried on Tn*917* that can be inserted into Tn*916* (Tn*3872*) ([@B5]; [@B6]).

Macrolide efflux/ribosomal protection is carried on the Macrolide Efflux Genetic Assembly (Mega), a 5.5 kb (Mega-1), or 5.4 kb (Mega-2) genetic element carrying *mef*(E) and *mel*, encoding a proton motive force efflux pump and a ribosomal protection protein ([@B47]; [@B18]; [@B42]). Mega is found in at least five locations in the pneumococcal genome (most common insertion classes being I, II, III, and IV) and also can be a component of larger genetic elements (e.g., insertion class V) ([@B18]; [@B16]; [@B6]). The *mef*(E)/*mel* operon confers resistance to 14- and 15-membered macrolides only (the M phenotype) and is inducible by these same macrolide molecules ([@B1]; [@B9]). In the United States, most pneumococcal macrolide resistance has been due to *mef*(E)/*mel* ([@B44]; [@B39]; [@B42]). Mega-mediated macrolide resistance has been generally reported as MICs of erythromycin as 1--16 μg/ml ([@B1]; [@B8]), and the clinical significance of Mega-mediated macrolide resistance has been debated ([@B10]).

*S. pneumoniae* isolates with both macrolide resistance determinants, *erm*(B) and Mega \[*mef*(E)/*mel*\], have been identified ([@B12]; [@B27]; [@B35]; [@B29]; [@B14]; [@B39]). In Atlanta, we documented the emergence and clonal expansion of macrolide-resistant serotype 19A clonal complex 320 isolates that contain Tn*2010*, containing both the *erm*(B) element in *orf*20 and Mega in *orf*6 of Tn*916* ([@B6]; [@B41]).

In this report, new high-level macrolide resistance of *S. pneumoniae* (MIC ≥ 16--256 μg/ml) due to the Mega element alone was identified and the genetic basis investigated. We also assessed the contribution of *erm*(B) and *mef*(E)/*mel* in the Tn*2010* dual element resistance isolates. Further, we found high-level macrolide resistance, regardless of mechanism, provided a competitive growth advantage during exposure to erythromycin.

Materials and Methods {#s1}
=====================

Bacterial Strains, Media, and Growth Conditions
-----------------------------------------------

The characteristics of *S. pneumoniae* strains used are listed in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}. A panel of 44 epidemiologically distinct, well-characterized Mega containing macrolide-resistant clinical isolates was investigated ([Table 1](#T1){ref-type="table"}). The *S. pneumoniae* isolates in this panel were selected from over 13,000 *S. pneumoniae* isolates identified through active prospective population-based surveillance of invasive pneumococcal disease in Atlanta between 1994 and 2011 ([@B43]; [@B6]). The isolates selected all contained the Mega element \[*mef*(E)/*mel*\] identified by PCR and/or nucleotide sequencing, and were chosen to evaluate resistance profiles based on the different locations of each Mega insertion site ([@B6]). Where possible, five strains for each insertion site were evaluated. Isolates were preferentially selected for which whole genome sequence data was available, and reflected a variety of capsule serotypes, antibiotic resistance phenotypes, and dates of isolation ([@B6]). For experiments, all *S. pneumoniae* strains were routinely grown on trypticase soy agar II containing 5% sheep's blood (blood agar) or in Todd-Hewitt broth containing 0.5% yeast extract (THY). Plate cultures were grown at 37°C with 5% CO~2~ and broth cultures were grown in a 37°C water bath.

###### 

*S. pneumoniae* isolates (including isolation year, serotype, MLST, clonal complex, and source) with Mega (genetic insertion site), *erm*(B), or both, and minimum inhibitory concentrations (MICs) to erythromycin.

  Mega                *erm*(B)   Strain    MIC^a^   iMIC^a,b^   Isolation year   Serotype   MLST      Clonal complex   Source
  ------------------- ---------- --------- -------- ----------- ---------------- ---------- --------- ---------------- ---------------
  Mega-1.I            None       GA17328   4        24          2000             6A         376       CC2090           [@B6]
                                 GA17457   8        48          2000             19A        199       CC199            [@B52]; [@B6]
                                 GA16857   4--6     24--32      2002             6A         376       CC2090           GAEIP
                                 GA41348   6--8     32          2004             19A        199       CC199            GAEIP
                                 GA41437   3        24          2004             6A         376       CC2090           [@B6]
                                 GA41502   4        32          2004             19A        199       CC199            GAEIP
  Mega-1.II           None       EU-NP04   4        16--24      2009             6C         2705      CC1379           [@B6]
                                 GA47033   4--6     16--24      2005             6C         4150      CC1379           [@B6]
                                 GA52306   4        12--24      2007             6C         3676      CC1379           [@B6]
                                 GA60190   8        16          2010             6C         1292      CC1379           [@B6]
  Mega-2.II           None       GA11757   16       48          2000             14         13        CC15             GAEIP
                                 GA16531   8        48          2001             6B         146       CC156            [@B6]
                                 GA17530   16       48          2000             14         81slv     --               GAEIP
                                 GA41538   16       64          2004             6A         384       CC156            [@B6]
                                 GA41688   16       48          2004             14         13        CC15             [@B6]
                                 GA62371   24       96          2011             35B        --        --               GAEIP
                                 GA64571   32       48          2012             35B        --        --               GAEIP
                                 GA67281   64       \> 256      2012             23A        --        --               GAEIP
                                 GA71819   48--64   \> 256      2013             23A        --        --               GAEIP
                                 GA71862   32       96          2013             35B        --        --               GAEIP
  Mega-1.III          None       GA17301   8        48          2000             9V         156       CC156            [@B6]
                                 GA17570   6        48          2001             9V         156       CC156            [@B6]
                                 GA18641   8--12    48--64      2002             9V         156       CC156            GAEIP
                                 GA41277   12--24   64          2004             19A        199       CC199            [@B6]
                                 GA47760   6--8     32          2006             11A        62        CC62             [@B6]
                                 GA62681   6--8     64          2011             15C        199       CC199            [@B6]
  Mega-2.IVa          None       GA04375   18       96          1995             19F        236       CC320            [@B6]
                                 GA14846   64       \> 256      2000             6B         1536      CC1536           GAEIP
                                 GA16242   64       \> 256      2001             6B         1536      CC1536           [@B6]
                                 GA16374   64       \> 256      2001             6B         1536      CC1536           GAEIP
  Mega-2.IVc          None       GA17545   64       \> 256      2000             6B         1536slv   CC1536           [@B6],[@B7]
  Mega-1.IVb          None       GA17828   16       64          2001             33F        2705      CC100            GAEIP
                                 GA19795   4        24          2004             33F        2705      CC100            GAEIP
                                 GA40189   2--3     24          2002             33F        2705      CC100            GAEIP
                                 GA41317   8        24--32      2004             33F        2705      CC100            [@B6]
                                 GA41318   8        32          2004             33F        2705      CC100            GAEIP
  Mega-1.V Tn*2009*   None       GA16833   4        32--48      2002             19F        5053      CC320            [@B6]
                                 GA17227   8--12    24          2000             23F        242       CC242            [@B6]
                                 GA17371   12       96          2000             19F        8014      CC320            [@B6]
                                 GA41301   12       32          2004             23F        242       CC242            [@B6]
                                 GA41565   3--4     32          2004             19A        81        CC81             [@B6],[@B7]
  Mega-1.VI           None       GA02254   3--4     16          1994             14         124       CC156            [@B6],[@B7]
                      Tn*3872*   GA47597   \> 256   \>256       2006             3          180       CC180            [@B6]
                      Tn*6002*   GA44194   \> 256   \>256       2005             19A        2543      CC63             [@B6]
  Mega-2.V Tn*2010*   Tn*2010*   GA11856   \> 256   \>256       2000             19F        271       CC320            [@B6]
                                 GA16121   \> 256   \>256       2000             19F        236       CC320            [@B6]
                                 GA44288   \> 256   \>256       2005             19A        320       CC320            [@B6]
                                 GA47688   \> 256   \>256       2006             19A        320       CC320            [@B6]
                                 GA47778   \> 256   \>256       2006             19A        320       CC320            [@B6]

a

MICs determined by Etest in at least duplicate and reported as μg/ml. Ranges provided when replicates varied, and each range is within a twofold dilution.

b

Subinhibitory concentration used for induction: 0.1 μg/ml.

###### 

Erythromycin minimum inhibitory concentrations (MICs) for *S. pneumoniae* strains and mutants \[Mega insertion, serotype, MLST (clonal complex)\] used in this study.

  Strain     Uninduced MIC^a^   Induced MIC^a,b^   Relevant genotype                                     References
  ---------- ------------------ ------------------ ----------------------------------------------------- ------------
  GA44288    \>256              \>256              Mega-1.V Tn*2010*, 19A, ST320 (CC320)                 [@B6]
  MS32       8                  64                 GA44288 Δ*erm*(B)::*aphA-3*                           This study
  MS41       \>256              \>256              GA44288 Δ*mef*(E)/*mel*::*cat*                        This study
  MS42       0.125^S^           ^∗^                GA44288 Δ*erm*(B)::*aphA-3*, Δ*mef*(E)/*mel*::*cat*   This study
  GA16242    64                 \>256              Mega-2.IVa, 6B, ST1536 (CC1536)                       [@B6]
  TS9001-3   0.125^S^           ^∗^                GA16242 Δ*mef*(E)/*mel*::*aphA-3*                     This study
  GA17545    96                 \>256              Mega-2.IVc 6B, ST1536slv (CC1536)                     [@B7]
  XZ8012-5   0.19^S^            ^∗^                GA17545 Δ*mef*(E)/*mel*::*aphA-3*                     This study
  NP112      0.19^S^            ^∗^                no macrolide resistance genes, 6B, ST1536 (CC1536)    [@B6]
  MS23       32                 \>256              NP112 +Mega-2.IVa                                     This study
  MS30       0.19^S^            ^∗^                MS23 Δ*mef*(E)/*mel*::*aphA-3*                        This study
  GA17457    8                  64                 Mega-1.I, 19A, ST199 (CC199)                          [@B52]
  XZ8009     0.125^S^           ^∗^                GA17457 Δ*mef*(E)/*mel*::*aphA-3*                     [@B52]
  MS27       32                 \>256              XZ8009 +Mega-2-IVa                                    This study

a

MICs reported as μg/ml.

b

Subinhibitory concentration used for induction: 0.5 μg/ml.

S

Susceptible to erythromycin when MIC ≤ 0.5 μg/ml.

∗

Susceptible strains were not tested for inducible MIC.

Antibiotic Susceptibility
-------------------------

To determine macrolide MICs, bacterial cultures were grown overnight on blood agar and subcultured onto blood agar or blood agar with 0.1 μg/ml erythromycin supplementation to induce resistance expression as a standard protocol in our laboratory ([@B52]; [@B9]). These overnight cultures were suspended to a density approximately equal to a 0.5 McFarland standard and streaked onto Mueller-Hinton agar containing 5% sheep's blood. Erythromycin susceptibility tests were performed by applying an erythromycin Etest strip (bioMérieux). After an overnight incubation, erythromycin susceptibility was measured. Uninduced MICs of 1--16 μg/ml were classified as resistant and those \>16 μg/ml were classified as high-level resistant.

General DNA Manipulation and Transformations
--------------------------------------------

To evaluate the basis for high level macrolide resistance in *S. pneumoniae*, a series of mutants were created ([Table 2](#T2){ref-type="table"}). Primer sequences are listed in Supplemental Table [A1](#SM3){ref-type="supplementary-material"}. PfuUltra II Fusion DNA polymerase (Agilent Technologies) or Q5 polymerase (New England Biolabs), restriction enzymes (New England Biolabs) and T4 DNA ligase (Invitrogen) were used for mutational cassette construction. Taq DNA polymerase (Applied Biosystems) or One Taq DNA polymerase (New England Biolabs) were used for screening putative mutants.

*S. pneumoniae* was transformed by a standard method that utilized the competence-stimulating peptide 1 (CSP-1) for induction of competence ([@B21]). CSP-1 was synthesized by the Emory University Microchemical Facility. Transformations were performed using plasmid DNA or PCR products and selected on blood agar containing kanamycin at 400 μg/ml, erythromycin at 1 μg/ml, or chloramphenicol at 3.2 μg/ml as described below. For mutants TS9001-3 and XZ8012-5, competent cells were transformed with a previously created plasmid that replaces *mef*(E) and *mel* with an *aphA-3* cassette and double crossover mutants were selected on kanamycin and confirmed by PCR and sequencing ([@B52]). This method was also used to delete *mef*(E)/*mel* from GA16242 to create TS9001-3 and from GA17545 to create XZ8012-5 ([Table 2](#T2){ref-type="table"}).

To generate mutants MS23 and MS27, a 10.9 kb PCR product containing Mega-2.IVa was amplified using primers SC173 and SC251 and purified using the QIAquick Gel Extraction kit. Purified PCR products were transformed into NP112 to create MS23 and XZ8009 to create MS27 and transformants were selected on erythromycin. Insertions were confirmed by PCR of the left and right junctions of Mega-2 in insertion site IVa with primers SC10 with SC173 and SC70 with SC251 ([Table 2](#T2){ref-type="table"}). For mutant MS30, MS23 was transformed with BamHI digested *mef*(E)/*mel*::aphA-3 plasmid. The desired double crossover was selected on kanamycin. The insertion was confirmed by PCR amplification of a 1521 bp product with primers SC125 and kanA ([Table 2](#T2){ref-type="table"}).

To generate mutant MS32, GA44288 genomic DNA was amplified upstream (primers MS34 and MS35) and downstream (primers MS36 and MS37), and regions of *erm*(B) were spliced by overlapping extension (SOE) to create an internal XbaI site using the PCR amplified regions with primers MS34 and MS37. The resulting 1066 bp product was digested with BamHI and PstI and cloned into double-digested pUC19 vector to create pMRS11. The kanamycin resistance cassette, *aphA-3* was PCR amplified from pSF151 ([@B48]) using primers MS53 and MS54 and the product was XbaI digested and cloned into pMRS11 to create pMRS13. The *aphA-3* cassette was confirmed to be in the forward direction by PCR with primers MS34 and MS54. Transformation of GA44288 cells with pMRS13 and selection on kanamycin to created strain MS32, which was confirmed by PCR amplification with primers MS27 and kanA as well as MS28 and kanC ([Table 2](#T2){ref-type="table"}).

Finally, to generate mutants MS41 and MS42, PCR amplification of the *mef*(E) upstream region by primers MS64 and MS72, the *mel* downstream region by primers MS63 and MS69, and the chloramphenicol cassette from pEVP3 ([@B11]) by primers MS70 and MS71 was performed. A single SOE PCR reaction with the three PCR products and primers MS63 and MS64 created a 2 kb Δ*mef*(E)/*mel*::cm^R^ cassette. This product was used for transformation and selection on chloramphenicol for GA44288 to create MS41 and MS32 to create MS42, which were confirmed by PCR amplification of a 2 kb product from primers MS63 and MS64 ([Table 2](#T2){ref-type="table"}).

qRT-PCR
-------

To determine *mef*(E)/*mel* expression, overnight blood agar cultures were first suspended in THY and grown to mid-log phase (OD~600~ = 0.3--0.5). Each culture was diluted to OD~600~ = 0.05 in prewarmed THY, grown to mid-log phase, and cultures were divided into tubes with or without erythromycin as indicated and continued to grow until the indicated treatment time was achieved. Culture aliquots were mixed with RNAprotect Bacterial Reagent (Qiagen) and RNA was isolated using the RNeasy Mini Kit (Qiagen). DNA was removed via the TURBO DNA-free (Applied Biosystems) and confirmed to be free of DNA by PCR using primers for genes of interest (Supplemental Table [A1](#SM3){ref-type="supplementary-material"}). QuantiTect Reverse Transcription Kit (Qiagen) was used to create cDNA from the purified RNA. qRT-PCR was performed using iQ SYBR Green Supermix (BioRad) with an iCycler iQ Real-Time Detection System (BioRad). qRT-PCR primers are listed in Supplemental Table [A1](#SM3){ref-type="supplementary-material"}. The measured C~T~ values were normalized using 16S rRNA, averaged, and wild type untreated condition was used to calculate the relative expression, ΔΔC~T~ value.

Competitive Index
-----------------

To determine if a competitive advantage resulted from high level macrolide resistance in *S. pneumoniae* competition assays were performed. Bacterial growth competitions were developed based on methods of [@B20]. Overnight blood agar cultures were subcultured onto blood agar with or without supplementation with erythromycin at 0.5 μg/ml. Each strain was suspended in THY broth with or without erythromycin (0.5 μg/ml), grown to OD~600~ = 0.5--0.7 before dilution to OD~600~ = 0.050 in fresh media. Diluted cultures were mixed (1:1) for competition assays or grown independently as non-competition controls and grown to OD~600~ = 0.5--0.7 and diluted 200-fold in fresh media. Cultures were subcultured three times allowing the cultures to grow for approximately 50 generations. Sampling of cultures was performed to monitor growth phase by OD~600~. At *T* = 0 and each time the cultures reached late-log/stationary phase, culture aliquots were collected, serially diluted in phosphate-buffered saline, and plated on blood agar without selection (total culture density) and selective blood agar (one of the mutants): kanamycin 400 μg/ml, erythromycin 1 μg/ml, chloramphenicol 3.2 μg/ml, or tetracycline 2 μg/ml. The competitive index (CI) was calculated as CI = (mutant CFU~output~/wildtype CFU~output~)/(mutant CFU~input~/wildtype CFU~input~) and a CI \< 1 indicates the mutant is less fit than then the wildtype.

Statistical Analysis
--------------------

Unpaired, two-tailed *t*-tests with 95% confidence intervals were performed using Prism^®^ 5 (GraphPad). For the growth competition experiments, the competitive index values of input were compared to the endpoint of 50 generations of growth.

Results
=======

Macrolide Resistance in *S. pneumoniae* Due to Mega
---------------------------------------------------

In a large population-based collection of over 13,000 *S. pneumoniae*, Mega-containing macrolide resistant pneumococcal isolates were identified (section Materials and Methods). [Table 3](#T3){ref-type="table"} shows the incidence of macrolide-resistant invasive pneumococcal disease (MR-IPD) 1999--2016 in Health District-3, Atlanta, GA, by macrolide resistance genotype across all ages before and after PCV7 introduction in 2000 and PCV13 introduction in 2010. Through 2016, 6 years after the introduction of PCV13 in the US, overall invasive pneumococcal disease was 6.94/100,000, macrolide resistance 2.0/100,000, *mef*(E)/*mel* resistance 1.11/100,000; and *erm*(B) resistance 0.67/100,000 ([Table 3](#T3){ref-type="table"}).

###### 

Incidence of macrolide-resistant invasive pneumococcal disease (MR-IPD) 1999--2016 in Health District-3, Atlanta, GA, by macrolide resistance genotype across all ages.

  Incidence                 1999^a^   2003^a^   2010^b^   2013^b^   2016^c^
  ------------------------- --------- --------- --------- --------- ---------
  Overall IPD               29.4      14.02     11.51     8.90      6.94
  Macrolide resistance      9.3       4.09      3.82      2.45      2.0
  Mega \[*mef*(E)/*mel*\]   7.7       3.49      1.60      1.50      1.11
  *erm*(B)                  1.5       0.22      0.74      0.63      0.67
  Dual resistance           ND        0.19      1.35      0.32      0.22

Incidence reported as cases per 100,000 population. Dual resistance strains are those that contain mef(E)/mel and erm(B). (Rare MR-IPD strains that were not PCR positive for erm(B) or mef(E)/mel may be ribosomal mutations or an unknown mechanism.) ND, not determined.

a

1999 prior to PCV7 (

Stephens et al., 2005

).

b

2010 prior to PCV13 (

Schroeder et al., 2017

).

c

This publication.

Forty-four macrolide resistant *S. pneumoniae* isolates were chosen for further study, and demonstrated a wide range of resistance to erythromycin with MICs of 2 to \> 256 μg/ml ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Isolates with erythromycin MICs of 1--16 μg/ml were classified as "resistant" and we defined isolates with MICs \> 16 μg/ml as "high-level resistant." After overnight induction with subinhibitory erythromycin (0.1 μg/ml), the erythromycin MICs for these strains increased to 16 to \> 256 μg/ml ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}).

![Macrolide resistance phenotypes and genotypes of *S. pneumoniae*. Erythromycin minimum inhibitory concentrations (MICs) were determined under uninduced conditions (black bars) and cultures induced with 0.1 μg/ml erythromycin (white bars). Each bar is the average MIC for a macrolide resistance genotype and strains in each group are detailed in [Table 1](#T1){ref-type="table"}.](fmicb-10-00868-g001){#F1}

The relationship of MIC to differences in the *mef*(E)/*mel* intergenic region and the genomic sites of Mega insertion was assessed. Mega type 1 (Mega-1) and Mega type 2 (Mega-2) ([@B18]), differentiated by a 99 bp insertion/deletion of the intergenic region between *mef*(E) and *mel*, did not contribute significantly to high-level macrolide resistance. Most Mega-1.II- and Mega-2.II-containing strains were found to have similar erythromycin and induced-erythromycin MICs ([Figure 1](#F1){ref-type="fig"}). Strains with chromosomal insertion sites Mega-1.I, Mega-1.II, Mega-2.II, Mega-1.III, Mega-1.IVb, and Mega-1.VTn*2009* typically have uninduced erythromycin MICs 2--16 μg/ml ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}), levels of macrolide resistance previously associated with Mega in *S. pneumoniae* ([@B18]; [@B1]; [@B9]), but with subinhibitory erythromycin induction MICs increased to 16--64 μg/ml ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). These isolates were also susceptible to clindamycin and thus have an M-phenotype. The newly described Mega-1.novel insertion ([@B6]), herein named Mega-1.VI, exhibited an MIC of 4 μg/ml and an induced-erythromycin MIC of 16 μg/ml.

Mega Only-Containing *S. pneumoniae* With High-Level Macrolide Resistance
-------------------------------------------------------------------------

*S. pneumoniae* containing Mega-2.IVa or Mega-2.IVc insertions exhibited intrinsic high-level macrolide resistance, with uninduced erythromycin MICs of \>18--256 μg/ml erythromycin and induced MICs of \>96 to \> 256 μg/ml erythromycin ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). The Mega-2.IVa and Mega-2.IVc isolates were found to be clindamycin susceptible (M phenotype). No other macrolide resistant determinants were found in these isolates, and mutation of the Mega element resulted in erythromycin sensitivity with MICs of 0.125 μg/ml ([Table 2](#T2){ref-type="table"}).

Macrolide Resistance in *S. pneumoniae* Containing *erm*(B) and *mef*(E)/*mel*
------------------------------------------------------------------------------

As anticipated, Mega-1.V Tn*2010* isolates containing both *erm*(B) and Mega ([@B14]) had uninduced erythromycin MICs of \>256 μg/ml and were clindamycin resistant (MLS~B~ phenotype). To better understand the relative roles of *mef*(E)/*mel* and *erm*(B) in high-level macrolide resistant Tn*2010*-containing *S. pneumoniae*, isogenic deletion mutations of *erm*(B) or *mef*(E)/*mel* or both were made in strain GA44288, an invasive pneumococcal disease isolate ([@B6]). The deletion of *mef*(E)/*mel* from GA44288, strain MS41 \[Tn*2010*Δ*mef*(E)/*mel*\], had no effect on erythromycin or clindamycin resistance, as MS41 remained highly resistant to erythromycin (MIC of \> 256 μg/ml) ([Table 2](#T2){ref-type="table"}). The deletion of *erm*(B) in GA44288 generated the mutant MS32 \[Tn*2010*Δ*erm*(B)\], which displayed an M phenotype with an erythromycin MIC of 8 μg/ml, an induced erythromycin MIC of 64 μg/ml ([Table 2](#T2){ref-type="table"}), and susceptibility to clindamycin. These MIC data for MS32 are consistent with the majority of Mega-only containing isolates ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). The deletion of the dual macrolide resistance determinants \[*mef*(E)/*mel* and *erm*(B)\] in GA44288 was designated MS42 \[Tn*2010* Δ*erm*(B)Δ*mef*(E)/*mel*\]. MS42 was susceptible to erythromycin (MIC 0.125 μg/ml) and clindamycin ([Table 2](#T2){ref-type="table"}). These data confirmed *erm*(B) and *mef*(E)/*mel* as the only macrolide resistance determinants in GA44288 and that the high-level macrolide resistance of Tn*2010*-containing *S. pneumoniae* was due to the presence of *erm*(B).

In *S. pneumoniae*, the expression of *mef*(E) and *mel* is controlled through transcriptional attenuation ([@B7]). Macrolide-induced ribosomal stalling results in deattenuation of *mef*(E)/*mel* to produce full-length polycistronic transcripts ([@B7]). To determine if *mef*(E)/*mel* was expressed in the presence of *erm*(B), *mef*(E) expression was measured by qRT-PCR from GA44288 after a 15 min exposure to erythromycin. The expression of *mef*(E) was dose-dependent, and 0.5 μg/ml erythromycin was sufficient to induce similar *mef*(E) expression in both the wild type and the *erm*(B) deletion mutant (data not shown). Thus, in isolates with both *erm*(B) and Mega, *mef*(E)/*mel* expression was induced by erythromycin and shown by the resistance data to result in a functional efflux pump/ribosomal protection protein.

*mef*(E)/*mel* Alone Was Responsible for High-Level Macrolide Resistance in Mega-2.IVa- and Mega-2.IVc-Containing *S. pneumoniae*
---------------------------------------------------------------------------------------------------------------------------------

The molecular basis for Mega-2.IVa and Mega-2.IVc isolates with high-level macrolide resistance but the M phenotype was further assessed. In the high-level macrolide-resistant strain GA16242 with a Mega-2.IVa insertion (uninduced erythromycin MIC of 64 μg/ml) *mef*(E)/*mel* was deleted to create TS9001. TS9001 was susceptible to erythromycin at 0.125 μg/ml ([Table 2](#T2){ref-type="table"}). Similarly, the deletion of *mef*(E)/*mel* from the high-level macrolide-resistant Mega-2.IVc strain GA17545 (uninduced erythromycin MIC of 64 μg/ml) resulted in susceptibility to macrolides as the erythromycin MIC of the mutant designated XZ8012-5 was 0.19 μg/ml ([Table 2](#T2){ref-type="table"}). Thus, *mef*(E)/*mel* alone in *S. pneumoniae* Mega-2.IVa and Mega-2.IVc isolates was responsible for high-level macrolide resistance.

To further confirm that the Mega class IVa and IVc insertions resulted in high-level macrolide resistance and determine whether the high-level macrolide resistance phenotype was transferable, the Mega-2.IVa insertion was transformed into the erythromycin susceptible strain NP112 (MIC 0.19 μg/ml). The resulting NP112 Mega-2.IVa isolate (designated MS23) demonstrated high-level macrolide resistance with an erythromycin MIC of 32 μg/ml and was inducible up to \>256 μg/ml ([Table 2](#T2){ref-type="table"}). The transfer of Mega-2.IVa included the adjacent IS*Smi*2 element and recreated the pneumococcal pathogenicity island (PPI-1) deletion found in Mega-2.IVa isolates ([@B6]). Deletion of *mef*(E)/*mel* from MS23 (designated MS30) restored macrolide susceptibility ([Table 2](#T2){ref-type="table"}). Mega-mediated high-level macrolide resistance was also transferred to the GA17457 Δ*mef*(E)/*mel* deletion strain (XZ8009). After transformation of XZ8009 with the Mega-2.IVa insertion (designated MS27), MS27 was found to have an erythromycin MIC of 32 μg/ml inducible up to \>256 μg/ml ([Table 2](#T2){ref-type="table"}).

High-Level Macrolide Resistance, Regardless of Mechanism, Provided a Competitive Advantage for Growth During Exposure to Erythromycin
-------------------------------------------------------------------------------------------------------------------------------------

To determine whether *erm*(B) and/or *mef*(E)/*mel* in *S. pneumoniae* provided a competitive advantage for growth during exposure to erythromycin, competitive assays using the clinical isolate GA44288 containing *erm*(B) and *mef*(E)/*mel* on Tn*2010*, and the strains with mutations in these genes ([Table 2](#T2){ref-type="table"}) were performed. Erythromycin-induced cultures of wild type strain GA44288 \[*erm*(B) and *mef*(E)/*mel* on Tn*2010*\] and the isogenic mutants MS32 \[Δ*erm*(B), *mef*(E)/*mel*\] and MS41 \[*erm*(B), Δ*mef*(E)/*mel*)\] ([Table 2](#T2){ref-type="table"}) were used in an *in vitro* competitive index (1:1 ratio). The concentration of erythromycin used is known to be achieved in human serum during treatment (0.5 μg/ml) ([@B30]). No significant difference in growth was observed between MS41 \[*erm*(B), Δ*mef*(E)/*mel*\] and the wild type strain GA44288 \[*erm*(B), *mef*(E)/*mel*\] in this assay ([Figure 2A](#F2){ref-type="fig"}, *p* = 0.5460). This suggested that *mef*(E)/*mel* did not provide a growth advantage to an *erm*(B)-containing strain during exposure to erythromycin. When MS32 \[Δ*erm*(B), *mef*(E)/*mel*\] was competed with GA44288 \[wild type, Tn*2010* with *erm*(B)*, mef*(E)*mel*\] the competitive index decreased to approximately 0.01 after 50 generations ([Figure 2B](#F2){ref-type="fig"}). These data indicated a significant growth advantage due to the high-level resistance encoded by *erm*(B) for GA44288 during exposure to erythromycin (*p* = 0.0012). Similarly, the competitive index of MS32 \[Δ*erm*(B), *mef*(E)/*mel*\] versus MS41 \[*erm*(B), Δ*mef*(E)/*mel*\] dropped to approximately 0.01 by the endpoint 50 generations ([Figure 2C](#F2){ref-type="fig"}, *p* \< 0.0001), again confirming the importance of *erm*(B)-induced high-level macrolide resistance during exposure to erythromycin. When these experiments were performed without erythromycin, the competitive indexes were at ∼1 throughout the course of the experiments (Supplemental Figure [A1](#SM1){ref-type="supplementary-material"}). Thus, in each of the erythromycin-induced competitive index experiments, an active *erm*(B)-containing strain (GA44288 and MS41) had a competitive advantage over the *erm*(B) deletion stain ([Figure 2](#F2){ref-type="fig"}). The data suggest that *erm*(B) provides a growth advantage when *S. pneumoniae* is exposed to treatment-level concentrations of erythromycin.

![The competitive index of isogenic GA44288 Tn*2010* mutants grown *in vitro* with erythromycin (0.5 μg/ml) for approximately 50 generations: **(A)** MS41 \[Tn*2010*Δ*mef*(E)/*mel*\] versus Tn*2010*, **(B)** MS32 \[Tn*2010*Δ*erm*(B)\] versus Tn*2010*, and **(C)** MS32 \[Tn*2010*Δ*erm*(B)\] versus MS41 \[Tn*2010*Δ*mef*(E)/*mel*\]. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001.](fmicb-10-00868-g002){#F2}

To determine whether the competitive advantage for growth of *erm*(B) during erythromycin exposure was due Erm(B)-mediated ribosomal methylation or to the high-level macrolide resistance of the *erm*(B)-containing strains, the competitive index assay was performed with the GA44288 isogenic strains in competition with GA16242, the Mega-2.IVa strain that produced high-level macrolide resistance due only to the presence of *mef*(E)/*mel* ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). The competitive index for GA44288 versus GA16242 remained ∼1 throughout the course of the experiments ([Figure 3A](#F3){ref-type="fig"}, *p* = 0.3088). The competitive index for MS41 \[*erm*(B), Δ*mef*(E)/*mel*\] versus GA16242 \[*mel*(E)/*mef*, Mega-2.IVa\] also did not change throughout the experiments ([Figure 3B](#F3){ref-type="fig"}, *p* = 0.4397). These data suggest that high-level macrolide resistance and not Erm(B)-mediated ribosomal methylation was responsible for the growth advantage in erythromycin. Finally, we assayed MS32 \[GA44288 Δ*erm*(B), *mel*(E)/*mef*\] with GA16242 and found the competitive index decreased below 0.1 after 50 generations of growth ([Figure 3C](#F3){ref-type="fig"}, *p* = 0.0316). Thus, both high-level macrolide resistance strains (GA44288 and GA16242), albeit generated by different mechanisms, provided the growth competitive advantage during exposure to erythromycin.

![The competitive index of high-level macrolide resistance strains with distinct mechanisms \[*erm*(B) and Mega-2.Iva\] *in vitro* with erythromycin (0.5 μg/ml) grown for approximately 50 generations: **(A)** GA44288 \[*erm*(B)-and *(*mef*(E)/*mel*-containing\] versus GA16242 (Mega-2.IVa-containing), **(B)** MS41 \[GA44288 Δ*mef*(E)/*mel, erm*(B)-containing\] versus GA16242 (Mega-2.IVa-containing), and **(C)** MS32 \[GA44288 Δ*erm*(B)\] versus GA16242 (Mega-2.IVa-containing). ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01.)*](fmicb-10-00868-g003){#F3}

Discussion
==========

In the United States, the rapid rise of macrolide resistance (includes resistance to erythromycin, azithromycin, clarithromycin and other 14- and 15-membered macrolides) in *S. pneumoniae* throughout the 1990s was due to the horizontal transfer and clonal expansion of stains containing the *mef*(E)/*mel* encoded efflux pump and ribosomal protection protein. The *mef*(E)/*mel* operon is found in the pneumococcal genome on the 5.4--5.5 kb Mega element ([@B44]; [@B39]). Mega-mediated pneumococcal macrolide resistance has generally been associated with lower levels of macrolide MICs (1--16 μg/ml to erythromycin) compared to high levels of macrolide resistance observed for *erm*(B) (usually \> 256 μg/ml to erythromycin) ([@B39]). The use of *in vitro* assays to query MIC values may be a limitation, however, macrolide resistance in the pneumococcus, caused by either *erm*(B) or *mef*(E)/*mel*-containing isolates, has been linked to treatment failures for lower respiratory tract infections and bacteremia ([@B24]; [@B26]; [@B40]; [@B52]). In one study by [@B19] 10/11 isolates from azithromycin treatment failures, who did not have underlying medical conditions, had the *erm*(B) (two patients) or Mega (eight patients) phenotype and three of the six available Mega-containing isolates had MICs ≥ 16 μg/ml.

We previously defined the genetic basis for the resistance mediated by the *mef(*E)/*mel*-containing Mega element in *S. pneumoniae*, demonstrated that *mef*(E) and *mel* are inducible by most 14- and 15-membered macrolides (including erythromycin, clarithromycin, and azithromycin) and by antimicrobial peptides, defined the Mega element that contains *mef*(E)/*mel*, identified the mechanism of macrolide induction of *mef*(E)/*mel*, demonstrated Mega's relationship to conjugative transposons, and mapped the locations of Mega in the pneumococcal genome ([@B18]; [@B52]; [@B9], [@B6],[@B7]). Mega elements are either type 1 or 2, distinguished by a 99 bp insertion/deletion (Mega-1 at 5.5 kb and Mega-2 at 5.4 kb) ([@B18]). Mega is found in the pneumococcal genome in six distinct sites, termed Mega classes ([@B6]). Insertion sites numbered I-IV were originally described ([@B18]). When inserted into *orf6* of Tn*916*-like elements, Mega is classified as insertion site V ([@B16], [@B14], [@B15]). Recently, we reported a new chromosomal insertion site, VI ([@B6]). Mega class IV has been further classified into three subclasses: Mega-2.IVa, Mega-1.IVb, and Mega-2.IVc all of which are upstream of the Pneumococcal Pathogenicity Island-1 (PPI-1) ([@B6]).

High-level macrolide resistance (MIC \> 16 μg/ml) due to Mega has been observed in clinical isolates ([@B19]; [@B39]) but has not been not characterized at a genomic level. We found high-level macrolide resistance in *S. pneumoniae* due to Mega related to specific genomic insertions Mega-2.IVa and Mega-2.IVc. We also have recent evidence of M-phenotype high-level macrolide resistance in Mega-2.II strains (unpublished data). Most Mega-2.IVa and Mega-2.IVc have high-level macrolide resistance while the Mega-1.IVb insertions have MICs similar to the other Mega insertion sites ([@B6]). The molecular mechanism of high-level macrolide resistance due to efflux and ribosomal protection in Mega-2.IVa/c and the newly discovered Mega-2.II isolates is not understood and is a limitation of this study, but is currently under investigation. One possibility is that high level macrolide resistance is related to genomic "trans" factors favoring higher expression the *mef/mel* operon, and this is associated with specific clonal complexes such as ST156 or ST15. Baseline MICs and *mef/mel* operon expression are elevated in strains with high level resistance. The 99-bp insertion in the intergenic region between *mef*(E) and *mel*, the distinguishing characteristic between Mega-1 from Mega-2, does not appear to significantly contribute to high-level macrolide resistance.

*S. pneumoniae* containing both macrolide resistance genetic elements, *mef*(E)/*mel* and *erm*(B), were first noted in the late-1990s from the US, Japan, and South Africa ([@B12]; [@B27]; [@B35]; [@B29]). Many of these strains were initially noted to belong to a single 19F multidrug resistant clone and subsequent work identified this clone as lineage Taiwan^19F^-14, or PMEN14 ([@B29]; [@B13]). Dual element macrolide-resistant serotypes, especially 19A *S. pneumoniae* belonging to CC320 (formerly CC271) a PMEN14 lineage ([@B15]; [@B4]; [@B6]), have increased steadily in the US and worldwide ([@B33]; [@B28]; [@B41]). For example, clonal expansion of dual macrolide-resistant 19A *S. pneumoniae* expanded dramatically in the US after the introduction of the pneumococcal conjugate vaccine, PCV7 ([@B33]). We documented the decline, 2010--2013 of serotype 19A (CC 320) with dual element macrolide resistance mechanisms following the introduction of PCV13 in 2010 ([@B41]). As part of this study, we analyzed our 2013--2016 population data set and isolate collection to further understand the impact of PCV13 on macrolide resistance in the population and the continued importance of the dual element resistance strains.

Through 2016, 6 years after the introduction of PCV13, the incidence of invasive pneumococcal disease has declined but the percent of these isolates that are macrolide resistance has remained at ∼30%. The *erm*(B)/*mef*(E)/*mel* dual element resistance strains continue to circulate with an incidence of 0.22/100,000 in the population ([Table 3](#T3){ref-type="table"}). These dual element resistance strains remain primarily 19A (CC320). While the samples for this study were collected from a defined geographic area, this potential limitation is moderated by the persistence of dual element resistant strains which were also observed throughout the US in 2016.

*S. pneumoniae* isolates with the dual element macrolide resistance genotype are carried on the mobile Tn*2010* and are multidrug resistant ([@B29]; [@B4]; [@B6]). Tn*2010* is a large 26⋅4-kb element with Mega \[*mef*(E)/*mel*\] and Tn*917* \[*erm*(B)\] inserted at two distinct sites into a Tn*916*-like conjugative transposon ([@B15]). A possible origin of Tn*2010* is via homologous recombination of a Tn*2009* (Mega-containing) strain acquiring a Tn*6002* fragment with *erm*(B) flanked by Tn*916 orf20*, or a Tn*6002* \[*erm*(B)-containing\] strain acquiring a *Tn2009* fragment with Mega flanked by Tn*916 orf*6 ([@B6]; [@B42]). This dual element macrolide resistance genotype results in an MLS~B~ phenotype with high-level macrolide resistance. These elements are not only able to transmit between co-resident serotypes of *S. pneumoniae* within the nasopharyngeal niche, but also have the possibility of transmitting to other naturally competent bacteria present in the nasopharynx, such as the clinically relevant *Haemophilus influenzae* ([@B25]).

In this study, we found both *mef*(E)/*mel* and *erm*(B) are expressed and functional in the Tn*2010* background. This indicates the co-expression of macrolide determinants in these strains. While high-level macrolide resistance of these *S. pneumoniae* isolates with the dual element macrolide resistance genotype was dominated by *erm*(B), which also confers resistance to lincosamides and streptogramin B, *mef*(E)/*mel* may provide other selective advantages. The presence of *mef*(E)/*mel* has been found to enhance resistance to the human antimicrobial peptide LL-37 ([@B52]). Thus, selective pressure for the acquisition and maintenance of both *mef*(E)/*mel* and *erm*(B) in *S. pneumoniae* may be encountered in human colonization and disease.

Antibiotic resistance determinants are often inducible and provide a selective advantage over non-resistant organisms in an antibiotic-containing environment. However, the expression of these determinants can be associated with a fitness cost ([@B2]). In the pneumococcus, *erm*(B) commonly is inducible and tightly regulated through translational attenuation ([@B32]; [@B31]). The *mef*(E)/*mel* operon is also tightly regulated but through transcriptional attenuation ([@B7]). While the expression of *erm*(B) in *S. pneumoniae* by a partial attenuator deletion did not cause a growth defect when the strain was grown *in vitro* as a pure culture ([@B51]), in *Staphylococcus aureus* deregulation of *erm*(C), a homolog of *erm*(B), results in increased expression of a subset of the proteome that causes a 10-fold fitness defect *in vitro* ([@B20]).

We found that *erm*(B) in *S. pneumoniae* did not cause a growth defect and provided a competitive advantage up to 100-fold over a lower-level resistant Mega-containing strain during growth in a macrolide containing environment. Insertions of *mef*(E)/*mel* causing high-level macrolide resistance when used in the competitive growth assays also provided a substantial growth fitness increase over the lower-level resistant *mef*(E)/*mel* phenotype when exposed to erythromycin. With a low fitness burden for maintenance of *mef*(E)/*mel* and/or *erm*(B), these determinants are unlikely to be lost from the pneumococcal population even with reduced use of antibiotics in clinical settings ([@B2]). Active efflux of the macrolide into the environment by Mega high-level resistant strains growing at high density may provide a further fitness advantage over low-level resistant strains.

An effective measure to date in combating antibiotic-resistant pneumococcal infections has been the introduction of pneumococcal conjugate vaccines ([@B44]). These vaccines provide individual protection for vaccinated individuals and reduce transmission of vaccine serotypes leading to herd protection for unvaccinated individuals in the same population ([@B38]). The targeted vaccine serotypes have often had the highest rates of antibiotic resistance determinants ([@B44]). However, as shown in the recent surveillance data macrolide resistance in genetic elements capable of horizontal transfer to new serotypes continues to persist in invasive *S. pneumoniae*.

In summary, likely driven by macrolide use in the population, high-level macrolide resistance in *S. pneumoniae* due to the Mega element alone has emerged, specifically in the context of the Mega-2.IVa or Mega-2.IVc and Mega-2.II genomic insertions. In addition, Tn*2010*-containing *S. pneumoniae* isolates that carry both *erm*(B) and *mef*(E)/*mel* have rapidly expanded with both resistant determinants functional in these strains. High-level macrolide resistance regardless of mechanism provides a competitive advantage for growth during exposure to macrolides.
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